These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33371161)

  • 1. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S; Lee Y; Kim TS; Kim SK; Han JY
    Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
    Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim [
    Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
    Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
    Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
    PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of interim
    Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of [
    Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
    Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What
    Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total metabolic tumor volume on
    Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
    Ziai D; Wagner T; El Badaoui A; Hitzel A; Woillard JB; Melloni B; Monteil J
    Cancer Imaging; 2013 Mar; 13(1):73-80. PubMed ID: 23466871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
    Ayati N; Lee ST; Zakavi SR; Cheng M; Lau WFE; Parakh S; Pathmaraj K; Scott AM
    J Nucl Med; 2021 Jul; 62(7):926-933. PubMed ID: 33246978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT.
    Kitajima K; Maruyama M; Yokoyama H; Minami T; Yokoi T; Nakamura A; Hashimoto M; Kondo N; Kuribayashi K; Kijima T; Hasegawa S; Yamakado K
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between
    Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
    J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ito K; Kitajima K; Toriihara A; Ishibashi M; Nakahara T; Daisaki H; Ohe Y; Honda R; Kijima T; Hasegawa S; Nakajo M
    Ann Nucl Med; 2021 Nov; 35(11):1253-1263. PubMed ID: 34370219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.